导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.93% | 1951/4773 |
| 近一周 | -1.88% | 3059/5465 |
| 近一月 | -0.95% | 977/5421 |
| 近一季 | -3.77% | 1683/5231 |
| 近半年 | -7.48% | 3354/4920 |
| 近一年 | 5.77% | 1665/4394 |
| 近两年 | 28.35% | 2358/2954 |
| 近三年 | 19.08% | 1523/2253 |
| 成立以来 | 94.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.40% 734/4961 |
1.70% 2999/5312 |
- - |
- - |
| 2025 | 6.75% 2948/4813 |
-4.43% 3176/3635 |
1.03% 2491/4076 |
7.08% 3480/4524 |
3.25% 712/4813 |
| 2024 | 16.81% 760/3463 |
9.09% 147/2808 |
2.15% 391/3014 |
6.21% 2864/3129 |
-1.30% 1647/3463 |
| 2023 | 6.57% 165/2656 |
15.35% 211/2280 |
1.12% 234/2385 |
-3.18% 863/2515 |
-5.64% 1437/2655 |
| 2022 | -13.20% 320/2207 |
-10.97% 463/1919 |
2.51% 1291/2016 |
-9.52% 286/2113 |
5.11% 487/2208 |
| 2021 | 26.11% 101/1822 |
2.69% 212/1255 |
3.68% 961/1330 |
16.88% 71/1466 |
1.33% 964/1822 |
| 2020 | 15.02% 785/1250 |
-6.07% 453/1028 |
0.44% 1002/1067 |
10.18% 576/1164 |
10.66% 586/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发央企创新驱动ETF联接A VS. 长安沪深300非周期A(740101) |